1608. Real-World Effectiveness of Long-Acting Cabotegravir + Rilpivirine in Virologically Suppressed Treatment-Experienced Individuals: Two Years of Data from the OPERA(®) Cohort

BACKGROUND: Cabotegravir + rilpivirine (CAB+RPV) injections, the first complete long-acting (LA) antiretroviral therapy (ART) regimen, was approved by the FDA in January 2021 for ART-experienced people with HIV (PWH) who are virologically suppressed (viral load [VL] < 50 copies/mL). We assessed t...

Descripción completa

Detalles Bibliográficos
Autores principales: Sension, Michael, Hsu, Ricky K, Fusco, Jennifer S, Brunet, Laurence, Cochran, Quateka, Sridhar, Gayathri, Vannappagari, Vani, van Wyk, Jean A, Wohlfeiler, Michael B, Fusco, Gregory P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678064/
http://dx.doi.org/10.1093/ofid/ofad500.1443

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678064/
http://dx.doi.org/10.1093/ofid/ofad500.1443

Ejemplares similares